Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance Summary. In 100 untreated patients with chronic lymphocytic leukaemia (CLL) lymphocyte doubling time (LDT) has been investigated in relationship with clinical stages, bone marrow histological patterns, treatment‐free period and survival. Although partially correlated with clinical stages and bone marrow patterns. LDT has a clear prognostic significance by itself: whereas a LDT of 12 or less months identifies a population of patients with poor prognosis, a LDT higher than 12 months is indicative of good prognosis as substantiated by a long treatment‐free period and survival. This simple parameter can be useful in the clinical management of CLL patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Haematology Wiley

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

Loading next page...
 
/lp/wiley/lymphocyte-doubling-time-in-chronic-lymphocytic-leukaemia-analysis-of-4yzoSVHe29

References (27)

Publisher
Wiley
Copyright
Copyright © 1986 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0007-1048
eISSN
1365-2141
DOI
10.1111/j.1365-2141.1986.tb02969.x
Publisher site
See Article on Publisher Site

Abstract

Summary. In 100 untreated patients with chronic lymphocytic leukaemia (CLL) lymphocyte doubling time (LDT) has been investigated in relationship with clinical stages, bone marrow histological patterns, treatment‐free period and survival. Although partially correlated with clinical stages and bone marrow patterns. LDT has a clear prognostic significance by itself: whereas a LDT of 12 or less months identifies a population of patients with poor prognosis, a LDT higher than 12 months is indicative of good prognosis as substantiated by a long treatment‐free period and survival. This simple parameter can be useful in the clinical management of CLL patients.

Journal

British Journal of HaematologyWiley

Published: Mar 1, 1986

There are no references for this article.